Waltham cancer biotech goes public in $118M IPO
Xilio Therapeutics, the Waltham-based cancer biotech that rebranded from Akrevia Therapeutics back in early 2020, has made its Wall Street debut. The company raised $117.5 million in an IPO on Friday, selling nearly 7.4 million shares at $16 apiece.
Xilio is trading on the Nasdaq under the symbol "XLO." Midday trading saw shares trading at just over $15 each, a drop of about 5%.
Sign up for the BioFlash e-newsletter, your free twice-weekly source for medical device and life sciences news in…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Health Management | Medical Devices | Pharmaceuticals